Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1 [0.8, 1.27]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.66 [1.07, 6.59]
Studies not reported
Low
Remission for at least 24 weeks · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher remission for at least 24 weeks compared with placebo (low certainty).
1 finding from 1 review
RR 9.5 [2.3, 39.21]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab may leads to higher durable remission within the first 24 weeks sustained until week 52 compared with placebo (low certainty).
1 finding from 1 review
RR 13 [1.75, 96.33]
Studies not reported
Low
Relapse · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab probably leads to lower disease relapse compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.68 [0.53, 0.86]
Studies not reported
Moderate
Disease flare · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 1.03 [0.96, 1.11]
Studies not reported
Low
Any serious adverse event · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any serious adverse event compared with placebo (low certainty).
1 finding from 1 review
RR 0.67 [0.35, 1.28]
Studies not reported
Low
Withdrawals due to adverse events · adults (age 18 years and older) with EGPA ANCA‐associated vasculitis
Mepolizumab showed no clear difference in any withdrawals due to AEs compared with placebo (low certainty).
1 finding from 1 review
RR 2 [0.19, 21.54]
Studies not reported
Low
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
Any measure of 'substantial' pain relief · rotator cuff disease
Shock wave therapy showed no clear difference in pain relief > 50%a compared with placebo (low certainty).
1 finding from 1 review
Pain Multiple scalese translated to VAS 0–10 (10 was severe pain)f · rotator cuff disease
Shock wave therapy showed no clear difference in pain Multiple scalese translated to VAS 0–10 (10 was severe pain)f compared with placebo (moderate certainty).
1 finding from 1 review
Functional outcomes · rotator cuff disease
Shock wave therapy probably leads to higher function Multiple scalese translated to Constant 0–100 scale (100… compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported success · rotator cuff disease
Shock wave therapy showed no clear difference in participant‐reported success compared with placebo (low certainty).
1 finding from 1 review
Quality of life · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participant withdrawals due to adverse events or treatment intolerance · rotator cuff disease
Shock wave therapy showed no clear difference in number of participant withdrawals due to adverse events or treatment… compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · rotator cuff disease
Shock wave therapy may leads to higher number of participants experiencing any adverse event compared with placebo (low certainty).
1 finding from 1 review
Outcomesa · Patients with osteoarthritis of the knee or hip
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants reporting an adverse event · patients with osteoarthritis
Tramadol in combination with acetaminophen probably leads to higher number of participants experiencing any adverse event compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with osteoarthritis
Tramadol in combination with acetaminophen may leads to higher number of participants who withdrew due to adverse events compared with placebo (low certainty).
1 finding from 1 review